These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 23390125)

  • 1. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ
    Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Eikelboom J; Yusuf S; Shestakovska O; Hart RG; Connolly S;
    Stroke; 2014 Jul; 45(7):2127-30. PubMed ID: 24916911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
    Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
    Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
    Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
    Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
    Romero-Ortuno R; O'Shea D
    Age Ageing; 2012 Mar; 41(2):250-4. PubMed ID: 22156597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.
    Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J
    Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.
    Chao TF; Lin YJ; Tsao HM; Tsai CF; Lin WS; Chang SL; Lo LW; Hu YF; Tuan TC; Suenari K; Li CH; Hartono B; Chang HY; Ambrose K; Wu TJ; Chen SA
    J Am Coll Cardiol; 2011 Nov; 58(23):2380-5. PubMed ID: 22115643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for the prevention of stroke in atrial fibrillation.
    Littrell R; Flaker G
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation.
    Sandhu RK; Bakal JA; Ezekowitz JA; McAlister FA
    Heart; 2011 Dec; 97(24):2046-50. PubMed ID: 22076011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.